On the morning of September 7, KINTOR PHARMA-B (09939) announced that its human long-term safety trial for KT-939, a novel and highly effective tyrosinase inhibitor developed in-house to suppress melanin production, had successfully concluded on September 4, 2026. Preliminary data revealed that a total of 114 subjects used KT-939 continuously for 52 weeks without any adverse skin reactions, consistent with the interim 28-week clinical results, fully demonstrating the favourable safety profile of KT-939. Driven by this positive news, the company's share price surged quickly after the market opened, climbing as much as 9.89% within half an hour to reclaim the HK$2 level.
Observations from the market indicate that since the release of the 26H1 earnings report on August 19, the stock has experienced a period of 'initial bottoming followed by a rebound.' The key question now is how far this rebound can carry the share price on the back of such positive catalysts.
Strong Consolidation at the Base: How Far Can the Oversold Recovery Extend?
Between May and July this year, despite the Phase III clinical data of the core pipeline asset KX-826 gaining recognition at international conferences and the commercialisation strategy being fully prepared, the overall liquidity in the Hong Kong stock market remained tight, investor risk appetite declined notably, and capital flowed out of high-volatility growth sectors. This market-wide valuation contraction had a significant impact on a company like KINTOR PHARMA-B, which relies heavily on future cash flows. As a result, the share price fell by nearly 50% during this period, briefly halving in value.
It was not until early August this year that the stock finally broke its downtrend, driven by three converging factors: the approach of a key fundamental milestone, supportive industry policies, and a shift in market style. This led to a 'six consecutive sessions of gains' from August 4 to August 12. After a technical pullback that bottomed on August 31, the stock once again entered a rebound phase.
From a chart perspective, between August 31 and September 4, KINTOR PHARMA-B displayed a robust consolidation structure characterised by 'volume expansion at the start, moderate volume growth during gains, extreme volume shrinkage during pullbacks, and renewed volume-driven advances.' Specifically, August 31 to September 3 represented a typical phase of active offensive action. During this period, daily trading volume expanded from 2.188 million shares to 2.651 million shares, with the price moving higher in tandem—a clear sign of simultaneous price and volume increases. Although the share price pulled back slightly on September 4, closing down 3.96%, the trading volume that day was only 851,000 shares, with turnover accounting for just 47.9% of the average daily turnover during the period, and the turnover rate a mere 0.17%. This pattern of declining price accompanied by shrinking volume suggests that on that day, funds were not fleeing the stock in droves but rather consolidating in a strong position.
Overall, the average daily volume on up days was approximately 2.5 times that of down days, while the On-Balance Volume (OBV) indicator rose from -4.143 million to 1.276 million. This further confirms that the price rebound was accompanied by net capital inflows, with external funds stepping in to absorb supply—far from a rally on thin or speculative volume.
The recent price-volume performance of KINTOR PHARMA-B is also corroborated on the technical front. Between August 31 and September 6, the stock was clearly in an accelerated phase of oversold recovery, displaying a bullish alignment across multiple moving average periods. In the short term, the 5-day and 10-day moving averages have turned upward and crossed above the 20-day average, although the 60-day average still presents medium-term resistance from above. On the Bollinger Bands, the price rebounded from near the lower band at HK$1.60 on August 28 to above the middle band, and on September 3, 4, and 7, it touched the upper band before pulling back, currently sitting in a relatively strong zone between the middle and upper bands.
However, despite the intraday surge on September 7, the volume ratio that day was only 0.57, indicating that while the price hit a new stage high, trading volume contracted notably, potentially signalling short-term momentum exhaustion. Additionally, on the technical side, the RSI6 indicator closed at 79.7 on September 3 and further rose to 82.4 by September 7, showing a scenario where the price has not reached new highs while RSI6 continues to climb—clear evidence of intensifying momentum. Yet, given the obvious volume shrinkage on September 7 compared to September 3, concerns about short-term price-volume divergence are already emerging.
Beyond Short-Term Gains: When Does Long-Term Value Arrive?
From a fundamental perspective, the 'beauty crossover' strategy that was previously met with market scepticism has now matured over recent years. The market's pronounced reaction to the September 7 announcement stems from the product highlighted in the release, KT-939, along with the high revenue growth expectations tied to the KOSHINÉ/KT-939 line. As per market insights, KT-939, independently developed by KINTOR PHARMA-B, is a tyrosinase inhibitor that efficiently blocks melanin production while also offering antioxidant and anti-inflammatory benefits. The company has previously disclosed that KT-939 significantly outperforms current mainstream whitening ingredients in human cell tyrosinase inhibition assays, cellular melanin production tests, and protein binding experiments.
As early as September 2025, all subjects for KT-939 had already been enrolled, initiating a 52-week continuous skin safety evaluation of a 0.2% KT-939 formulation. Interim results showed that all 119 subjects using KT-939 for 28 consecutive weeks reported no adverse skin reactions, including cosmetic contact dermatitis, photoallergic dermatitis, pigmentary skin disorders, contact urticaria, and cosmetic acne. From a market standpoint, data shows that China's whitening and spot-reducing functional cosmetics market reached RMB 128.93 billion in retail sales in 2025, a year-on-year increase of 20.6%. Competition in this red ocean market has become fierce, forcing brands to craft new narratives—this is precisely why companies are racing to develop novel whitening ingredients. The 52-week data from the long-term human safety trial further validates KT-939's efficacy and safety profile, solidifying KINTOR PHARMA-B's position in the highly competitive whitening ingredient and new product market.
Nevertheless, compared to KT-939, the NDA advancement of the core product KX-826 and its subsequent commercial ramp-up may be the more critical driver of the company's medium-to-long-term share price elasticity. On July 10, 2024, KINTOR PHARMA-B announced the commercial launch of a cosmetic product featuring KX-826 as its primary ingredient. Its first product is a topical anti-hair loss liquid targeting androgenetic alopecia (AGA). It is evident that, although classified as a cosmetic, the product targets the same hair loss market as AGA treatments. According to a GrandViewResearch report, the global hair loss treatment market was valued at US$8.2 billion in 2022, expected to grow at a compound annual growth rate (CAGR) of 9.0% from 2023 to 2030, reaching an estimated US$16.02 billion by 2030.
Based on the 26H1 earnings report released on August 19, revenue for the period increased from RMB 6 million in the prior-year period to RMB 52 million for the six months ended June 30, 2026, while net loss narrowed 8.99% year-on-year to RMB 75.782 million. The revenue increase was primarily driven by live-stream e-commerce sales boosting global sales of the new premium cosmetics brand KOSHINÉ, whose core ingredient KX-826 is one of the company's flagship products.
From a product strategy standpoint, KX-826 is undoubtedly the core asset determining the company's valuation ceiling. This drug candidate is not merely a cosmetic ingredient but a potential first-in-class topical AR antagonist. Should KX-826 secure approval and scale successfully, it could drive the market to shift its valuation framework for the company from a 'small-cap loss-making biotech with beauty sales' to a 'commercial platform for innovative hair loss therapeutics.' According to the company's prior plans, KX-826 is expected to be submitted for NDA in the second half of this year, with anticipated approval in the second half of 2027. The company's stated objectives are 'rapid ramp-up post-approval' and 'sales targets exceeding RMB 100 million.' For bullish investors, the present moment may well be the critical juncture to position for the successful execution of these medium-to-long-term plans.